ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
ALXO Stock Chart & Stats
$1.97
$0.01(0.54%)
At close: 4:00 PM EST
$1.97
$0.01(0.54%)
Day’s Range― - ―
52-Week Range$0.40 - $2.66
Previous CloseN/A
Volume579.15K
Average Volume (3M)670.12K
Market Cap
$259.27M
Enterprise Value$95.67M
Total Cash (Recent Filing)$44.79M
Total Debt (Recent Filing)$5.22M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
May 07, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding131,608,280
10 Day Avg. Volume555,214
30 Day Avg. Volume670,121
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.33
Price to Sales (P/S)0.00
P/FCF Ratio-0.72
Enterprise Value/Market Cap0.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.96
Forecast
1Y Price Target
$4.75Price Target Upside141.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.72
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker-enriched EfficacyAnalyst points to biomarker analyses that found stronger responses in patients with high CD47 expression when evorpacept is combined with HER2-targeted therapy, indicating patient selection could improve trial outcomes.
Drug Design And SafetyAnalyst highlights that ALX2004's novel epitope binding, linker and proprietary payload aim to improve potency while early dose escalation showed no dose-limiting toxicities, suggesting a cleaner safety profile versus some competitors.
Regulatory Pathway And Partner ValidationAnalyst notes the ASPEN-09 study redesign strengthens the analysis to support planning of a potential registrational trial, and a partner advancing a randomized evorpacept combination signals external interest in the program.
Bears Say
Clinical-readout DelayAnalyst warns that postponement of ASPEN-09 topline results removes a key clinical-readout catalyst and increases uncertainty around the program's value drivers.
Reduced Data Flow And VisibilityAnalyst notes cancellation of the planned interim data update will reduce the flow of clinical readouts, lowering investor visibility and potentially increasing share price volatility.
ALX Oncology Holdings News
ALXO FAQ
What was ALX Oncology Holdings’s price range in the past 12 months?
ALX Oncology Holdings lowest stock price was $0.40 and its highest was $2.66 in the past 12 months.
What is ALX Oncology Holdings’s market cap?
ALX Oncology Holdings’s market cap is $259.27M.
When is ALX Oncology Holdings’s upcoming earnings report date?
ALX Oncology Holdings’s upcoming earnings report date is May 07, 2026 which is in 32 days.
How were ALX Oncology Holdings’s earnings last quarter?
ALX Oncology Holdings released its earnings results on Feb 27, 2026. The company reported -$0.42 earnings per share for the quarter, missing the consensus estimate of -$0.362 by -$0.058.
Is ALX Oncology Holdings overvalued?
According to Wall Street analysts ALX Oncology Holdings’s price is currently Undervalued.
Does ALX Oncology Holdings pay dividends?
ALX Oncology Holdings does not currently pay dividends.
What is ALX Oncology Holdings’s EPS estimate?
ALX Oncology Holdings’s EPS estimate is -0.19.
How many shares outstanding does ALX Oncology Holdings have?
ALX Oncology Holdings has 131,608,280 shares outstanding.
What happened to ALX Oncology Holdings’s price movement after its last earnings report?
ALX Oncology Holdings reported an EPS of -$0.42 in its last earnings report, missing expectations of -$0.362. Following the earnings report the stock price went down -10.213%.
Which hedge fund is a major shareholder of ALX Oncology Holdings?
Currently, no hedge funds are holding shares in ALXO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ALX Oncology Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.75 (141.12% Upside)
$4.75 (141.12% Upside)
Hedge Fund Trend
Increased
By 627.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 15.4%
Last 30 Days ▲ 15.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.66%
12-Months-Change
Fundamentals
Return on Equity
-118.95%
Trailing 12-Months
Asset Growth
-55.59%
Trailing 12-Months
Company Description
ALX Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
ALXO Company Deck
ALXO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasizes multiple encouraging clinical signals for evorpocept (EVO) — including biomarker‑driven responses across gastric, breast and NHL settings — and steady clinical progress for the ALX 2004 ADC. The company materially strengthened its balance sheet with a recent equity financing providing runway through 2028 and reduced quarterly operating losses year‑over‑year. Key risks remain: several datasets are early and small, biomarker cut‑point and prevalence uncertainty prompted an upsizing of ASPEN, safety and therapeutic window for the ADC must be confirmed clinically, and several important readouts are still 12–18 months away. Overall, positive clinical validation and a strong financing event outweigh the staging‑related uncertainties.View all ALXO earnings summariesALXO Stock 12 Month Forecast
Average Price Target
$4.75
▲(141.12% Upside)
Technical Analysis
Ownership Overview
10.30% Insiders
1.45% Mutual Funds
13.26% Other Institutional Investors
73.92% Public Companies and
Individual Investors